Tirzepatide activates two pathways Ozempic cannot reach.
Tirzepatide is the first dual GLP-1 and GIP receptor agonist — producing greater weight loss than semaglutide in head-to-head data. Available through physician evaluation as a compounded formulation.
· Physician evaluation required· Licensed 503A pharmacy· All 50 US states· 24hr review
GLP-1
GIP
Tirzepatide activates both
GLP-1
Semaglutide — GLP-1 only
22%
Average weight loss in SURMOUNT-1
2×
Receptor pathways vs semaglutide
Compounded tirzepatide is not FDA-approved. Physician evaluation required. Not equivalent to Mounjaro or Zepbound.
How does the GIP receptor make tirzepatide different?
GLP-1 receptor
The GLP-1 pathway suppresses appetite, slows gastric emptying, and stimulates insulin secretion — the mechanism behind semaglutide. Tirzepatide activates GLP-1 at least as potently as semaglutide.
GIP receptor — the difference
GIP (glucose-dependent insulinotropic polypeptide) directly affects fat cell metabolism. GIP receptor activation enhances fat breakdown, reduces fat storage, and improves the metabolic effects of GLP-1 — producing significantly greater weight loss through dual pathway activation.
The SURMOUNT-1 trial demonstrated that tirzepatide at 15mg produced an average weight loss of 22.5% at 72 weeks — substantially greater than the 14.9% seen with semaglutide in the comparable STEP 1 trial. While no direct head-to-head trial has been conducted, the difference in mechanism appears to produce meaningfully greater weight loss outcomes in comparable populations.
Source: Jastreboff et al. NEJM 2022 (SURMOUNT-1).
How much weight do you lose on tirzepatide?
22.5%
Average weight loss
Average weight loss at 72 weeks in SURMOUNT-1 at 15mg dose. The highest weight loss ever recorded in an obesity drug trial at time of publication.
NEJM 2022
91%
Lost ≥5% body weight
Of participants lost ≥5% body weight at 15mg dose in SURMOUNT-1 — vs 35% in the placebo group.
NEJM 2022
40%
Lost ≥25% body weight
Of participants lost ≥25% of body weight in SURMOUNT-1 — approaching surgical levels of weight reduction.
NEJM 2022
2.4%
HbA1c reduction
HbA1c reduction in SURPASS-2 trial for type 2 diabetes — superior to semaglutide in head-to-head comparison.
Lancet 2021
Data reflects FDA-approved tirzepatide (Mounjaro/Zepbound). Compounded tirzepatide has not been evaluated in clinical trials.
Is tirzepatide better than semaglutide?
Feature
Semaglutide
Tirzepatide
Receptor targets
GLP-1
GLP-1 + GIP
Average weight loss
~15%
~22%
Approved for diabetes
✓ Ozempic
✓ Mounjaro
Approved for obesity
✓ Wegovy
✓ Zepbound
Dosing frequency
Weekly
Weekly
Administration
Subcutaneous injection
Subcutaneous injection
Manufacturer
Novo Nordisk
Eli Lilly
No direct head-to-head randomized trial has compared semaglutide and tirzepatide for weight loss. Comparison is based on separate trial populations and may not represent equivalent results in the same patient.
Compounded tirzepatide vs Mounjaro and Zepbound.
Compounded tirzepatide is not the same as FDA-approved Mounjaro or Zepbound. It is not manufactured by Eli Lilly and has not been evaluated by the FDA.
Mounjaro received FDA approval for type 2 diabetes in 2022. Zepbound received FDA approval for chronic weight management in 2023. Both are manufactured by Eli Lilly and subject to FDA quality and safety review.
Compounded tirzepatide is prepared by licensed 503A compounding pharmacies using pharmaceutical-grade active pharmaceutical ingredients (API). The 503A framework allows licensed pharmacies to compound medications for individual patient prescriptions under physician supervision.
The same active ingredient — different regulatory pathway, different manufacturer, different quality review process. Your physician will help you understand whether compounded tirzepatide is appropriate for your clinical situation.
Who may qualify
✓BMI of 30 or greater
✓BMI of 27+ with a weight-related condition (hypertension, type 2 diabetes, high cholesterol, sleep apnea, or cardiovascular disease)
✓No personal or family history of medullary thyroid carcinoma (MTC) or MEN2
✓No history of pancreatitis
✓Not pregnant or planning pregnancy
✓Willing to commit to physician monitoring
Common side effects
Nausea (most common)
Diarrhea
Vomiting
Constipation
Decreased appetite
Injection site reactions
Muscle loss (documented at higher doses)
Muscle loss note
Tirzepatide-related muscle loss is a documented concern. kindr's GLP-1 Shield and Muscle Protect are formulated to address this. See GLP-1 Shield →
Request your physician evaluation.
Complete this form to be evaluated for compounded tirzepatide. A licensed physician will review your submission within 24 hours.
Compounded tirzepatide is not FDA-approved. Not equivalent to Mounjaro or Zepbound. Physician evaluation required. Prescription not guaranteed. Clinical services by Arora Health & Aesthetics, LLC. Compounded by VialsRX.
Frequently asked questions.
Tirzepatide is a dual GLP-1 and GIP receptor agonist — the first medication to activate both hormone pathways simultaneously. It is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, both manufactured by Eli Lilly. Compounded tirzepatide available through kindr Health is prepared by VialsRX, a licensed 503A compounding pharmacy.
The dual agonist. Physician-supervised. Start today.
Compounded tirzepatide available through kindr Health is prepared by VialsRX under Section 503A of the Federal Food Drug and Cosmetic Act. It is not an FDA-approved drug and is not equivalent to Mounjaro or Zepbound. Clinical services provided by Arora Health & Aesthetics, LLC. Prescription required. Not guaranteed. This page is for informational purposes and does not constitute medical advice.
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer NPI 1689841744 · Last reviewed: May 10, 2026
Hormone therapy addresses the hormonal causes of midlife weight gain. GLP-1s like semaglutide target appetite and metabolism. Here is how they differ — and when to use one, the other, or both.